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a  b  s  t  r  a  c  t
Polycystic  ovary  (PCO)  is  a highly  variable  condition  with  a wide  array  of  presentations.  The
polycystic ovary  syndrome  should  meet  at least  two  of  the following  three  criteria:  oligo-  or
anovulation; clinical  and/or  biochemical  signs  of hyperandrogenism;  polycystic  ovaries  on
ultrasound.  The  prevalence  of  PCO  is  largely  unknown  in Saudi  Arabia.  This  study  presents
the  prevalence  of PCO  in young  unmarried  female  students  of  Taibah  University  Almadinah
Almunawwarah,  presenting  with  menstrual  irregularities.  The  agreed  ultrasound  featuresKeywords:
Polycystic ovary
Ultrasound
Polycystic ovary syndrome
Ovarian  follicle
of PCO i.e.  presence  of  12 or more  2–9 mm  ovarian  follicles;  a peripheral  distribution  of
ovarian  follicles;  an  ovarian  volume  of  more  than  10 cm3 and  a highly  echogenic  ovarian
stroma  were  analyzed  in all  108  patients.  The  criteria  of  12  or more  2–9  mm  ovarian  follicles
were  found  to have  highest  sensitivity  in establishing  the diagnosis  of  PCO.
© 2013  The  Saudi  Society  of Microscopes.  Production  and  hosting  by  Elsevier  Ltd.1. Introduction
Polycystic ovary syndrome (PCOS) is a malfunction
with ovarian overproduction of androgens with main
features of hyperandrogenism and an ultrasound appear-
ance  of polycystic ovaries [1]. The European Society of
Human  Reproduction and Embryology/American Society
for  Reproductive Medicine criteria, often called Rotterdam,
includes various phenotypes based on a combination of
any  two of the three ﬁndings of hyperandrogenism, men-
strual  irregularity, and polycystic ovaries on ultrasound
[2]. However, a wealth of literature agrees that women
may  present an appearance of PCO at ultrasound without
any  sign of androgen excess, although with indicators of∗ Tel.: +966 48460008.
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Open access under CC BY-NC-ND license.ovarian dysfunction [3]. PCOS remains a syndrome and as
such,  no single diagnostic feature is sufﬁcient in itself to
establish  the clinical diagnosis. Similarly, PCOS is diagnosed
by  exclusion, and disorders having a phenotype related to
that  of PCOS must be ruled out; such as congenital adrenal
hyperplasia, Cushing syndrome and virilising tumors [4].
Since  the advent of ultrasound, numerous diagnostic
parameters have been coined to morphologically deﬁne
PCO,  but there is still no consensus as to their respec-
tive diagnostic value. The present study aims to report
prevalence of PCO in students of Taibah University with
an  overview of the salient ultrasound features of PCO.
2.  Materials and methods
This  cross sectional clinical study was conducted at
the  Medical Center of Taibah University Almadinah Almu-
nawwarah Saudi Arabia during the period January 2012
through December 2012. All consecutive unmarried female
students  of Taibah University (faculties of medicine, sci-
ence,  literature, and computer sciences), with menstrual
Open access under CC BY-NC-ND license.irregularities, acne, and hirsutism, aged 18–28 years were
recruited in the study. Students with diabetes mellitus, thy-
roid  and adrenal disorders and on hormonal replacement
therapy (HRT) were excluded from the study. Menstrual
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Table 1
Manifestations of PCO in term of clinical and menstrual abnormalities in
the  study (N = 108).
No. Features No. (%)
1 Age (years) 21.3 ± 2.1
2  Patients with hirsutism 39 (36.1)
3 Patients with acne 34 (31.4)
4 Patients with hirsutism and acne 58 (53%)
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ature chart and/or serum progesterone level < 3 ng/ml in
luteal  phase)], with either one biological criterion (serum
LH  levels > 6.5 UI/l, and/or testosterone levels > 0.7 ng/ml,
and/or androstenedione levels > 2.2 ng/ml), or an ovarian
Table 2
Ultrasound features of polycystic ovaries in the study (N = 108).
Diagnostic criteria for PCO Mean ± SD
Mean FNPO 28.7 ± 9.5
Maximum FSSP 14.8 ± 3.75  Patients with oligomenorrhea 87 (80.5)
6 Patients with amenorrhea 21 (19.5)
rregularities were deﬁned as; chronic anovulation as
menorrhea of 3 months duration or oligomenorrhea as
ntermenstrual interval > 35 days. Regular menstruation
as deﬁned as 9–16 cycles of a 21–35 days duration within
 year and no more than a 4-day difference in duration
etween cycles [5]. The participants had pelvic ultrasound
can with full bladder, and those found to have ultrasound
riteria of PCO were included in the ﬁnal group and the
ata  was stored on Microsoft Excel for further analysis. The
valuated  ultrasound criteria of PCO were; the presence of
2  or more 2–9-mm ovarian follicles; a peripheral distri-
ution of ovarian follicles; an ovarian volume of more than
0  cm3 and a highly echogenic ovarian stroma [6]. Only one
vary  ﬁtting this deﬁnition was considered enough to label
CO  [2]. All ultrasonic examinations were performed by a
ingle,  experienced sinologist. Ethical approval was  taken
rom  the Institution Review Board and a written informed
onsent was taken from all the participants.
Transabdominal ultrasound was performed between
ycle days 2 and 7 or during any day of amenorrhea,
tilizing a 6 MHz  curved-array scanner of transabdomi-
al transducer (Toshiba Ultrasound System Nemio20 CA)
ith  a full urinary bladder. Ultrasound measurements were
aken  in real time, according to a standardized protocol.
ain settings were optimized with particular attention to
he  size of the patient and the amount of pelvic fat. After
dentiﬁcation of the ovaries, the size of the ovary was
easured in three orthogonal planes. The highest possible
agniﬁcation was used to examine the ovaries. After the
ongest  medial axis of the ovary had been measured, the
varian  length and thickness were outlined and the area
as  calculated using an automatic ellipse to outline the
vary  as reported previously [7].
. Results
From a cohort of 201 participants, 108 (53.7%) were
iagnosed to have PCO with a mean age of 21.3 ± 2.1 years.
he  demographic details, menstrual irregularities and der-
atological manifestations reported in 108 cases of PCO
re  illustrated in Table 1.
The ultrasound criteria of 12 or more follicles measuring
–9 mm was the commonest ﬁnding observed in 97 (89.8%)
atients, followed by the peripheral distribution of ovarian
ollicles in 89 (82.8%) as shown in Fig. 1.
Various radiological parameters shown by ultrasound
can are summarized in Table 2.
The ultrasound images from two patients with PCO are
isplayed in Figs. 2 and 3.Fig. 1. The distribution of ultrasound criteria of PCOS in the study
(N = 108).
4. Discussion
March et al. conducted a retrospective birth cohort
study in which 728 women  born during 1973–1975 in a
single  maternity hospital were traced and interviewed in
adulthood  (age ¼ 27–34 year; n ¼ 728 [8]. They reported a
representative prevalence estimate of PCO in the commu-
nity  under the National Institutes of Health (NIH) criteria
and  the more recent Rotterdam consensus criteria and
Androgen Excess Society (AES) criteria. They estimated that
the  prevalence of PCO using the NIH criteria was 8.7 + 2.0%
(with  no need for imputation). Under the Rotterdam crite-
ria,  the prevalence was  11.9 + 2.4% which increased to
17.8  + 2.8% when imputed data were included. Under the
AES  recommendations, PCO prevalence was 10.2 + 2.2%,
and  12.0 + 2.4% with the imputed data. In the present study,
the  estimated prevalence was  53.7% which is strikingly
higher than the previous data. One of the explanations may
be  the high incidence of obesity in Saudi Arabia which has
an  established association with PCOS. A study conducted on
29–43-year-old Saudi female patients with suggested diag-
nosis  of PCOS illustrated the prevalence of 64.5% obese and
24.2%  overweight cases [9]. Similarly, other investigators
have described a high prevalence of obesity with infertility
and  PCOS [10–12].
The  diagnosis of PCOS is based on the association
of one clinical criterion [hirsutism (as assessed by a
modiﬁed Ferriman and Gallwey score of >8) [13] or
menstrual disturbances (i.e. oligomenorrhoea or amenor-
rhoea or cycle length either < 25 days or >35 days and/or
ovulatory disturbances as assessed by basal body temper-Ovarian volume 16.8 ± 5.3
FNPO; follicle number per ovary; FSSP; follicle in a single sonographic
plane; ovarian volume in cm3.
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Fig. 2. (A and B): Transabdominal scan of right ovary showing more than 12 perip
echogenic  central ovarian stroma, while in B, ovarian volume of 19.4 cm3 is calcuFig. 3. Another patient showing enlarged ovary with bright echogenic
stroma and peripheral distribution of follicles more than 12 in number
seen on a single sonographic plane.
area > 10 cm2 unilaterally or bilaterally at ultrasound
[14,15]. Blood sampling is performed during the early
follicular phase i.e. between days 2 and 7 after the last men-
strual  period which is either spontaneous or induced by the
administration of didrogesterone (10 mg/day for 7 days).
This  reﬂects the complex nature of PCOS and the treating
physician must note that every single clinical, menstrual,
hormonal and biochemical parameter will not be encoun-
tered  in each patient.
The  prevalence of hirsutism associated with PCO in this
study  (39%) was higher than a Greek prevalence study of
29%  [16] and three other PCOS prevalence studies [17–19].
The  lower hirsutism prevalence in other studies may  be a
reﬂection  of alternate methodologies and selection criteria
employed for deﬁning hirsutism.
Pelvic ultrasound is important not only for the deﬁnition
of  polycystic ovary syndrome but also for detecting andro-
gens  producing ovarian tumors and sexual development
abnormalities [20]. The ultrasound criteria for polycystic
ovary are the presence of 12 or more follicles measuring
2–9 mm in diameter or an ovarian volume greater than
10  cm3 in at least one ovary. If a single follicle is greater
than 10 mm in largest diameter, the ultrasound should
be  repeated later to calculate again the ovarian volumeherally distributed follicles all measuring around 4 mm in diameter with
lated.
and  area. The peripheral distribution of follicles in “string
of  pearls” and hyperechogenicity of the stroma are clas-
sical  ultrasound features [21]. Both hormonal work-up
and ultrasound should be carried out without hormonal
contraception. In the present study, the highest sensitiv-
ity  for the ultrasound criteria of PCO was found to be
12  or more 2–9 mm  follicles found in 97 (89.8%) cases.
This ﬁnding substantiates the theory of follicular arrest,
which proposes that the progression of small antral fol-
licles  to selected follicles (6 ± 9 mm in size) and to the
dominant follicle cannot proceed normally in PCO [22].
This  phenomenon is crucial in determining the anovula-
tion of PCO, and it has been shown to be closely related
to  obesity and hyperinsulinism. Since ultrasound can only
detect  follicles > 2 mm in size, the multifollicular nature
of  PCO can be confused with the other causes of multi-
follicular ovaries (MFO) in which only the latest stages
of  follicular development (>4 mm)  are involved. Indeed,
MFO  are observed by ultrasound in various physiologi-
cal and pathological situations, such as mid  ± late normal
puberty, central precocious puberty, hypothalamic anovu-
lation,  hyperprolactinaemia [15]. This raises the question
of  which threshold should be accepted if follicle number
per  ovary is used to diagnose PCO. The majority of authors
have  set this threshold at 10 (Adams et al., 1985; Takahashi
et  al., 1994) but some authors have recommended 15 (Fox
et  al., 1991).
Although increased stromal ovarian volume is a char-
acteristic feature of PCO [23], determination of ovarian
size has been shown to be a good replacement for
quantitation of stromal volume in clinical practice. This
deﬁnition does not apply to women using oral contra-
ceptives since the latter can alter ovarian morphology
in normal women and possibly in subjects with PCO
[24]. A study calculated stromal index (ratio of mean
stromal echogenicity to mean echogenicity of the entire
ovary) and total stromal echogenicity [25]. There was no
difference in the mean stromal echogenicity, although
the stromal index was  signiﬁcantly greater in women
with PCO. The apparent subjective increase in stromal
echogenicity in PCO, as exempliﬁed by the greater stro-
mal  index, was due to a combination of the increased
opy and
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olume of ovarian stroma and the signiﬁcantly lower mean
chogenicity of the entire ovary in these women. Simi-
ar  results were demonstrated in 67 (62%) patients which
eﬂect  low sensitivity of ovarian echogenecity in diagnos-
ng  PCO.
Transabdominal ultrasound has been largely super-
eded by transvaginal scanning because of greater
esolution, and patient preference, as the need for a full
ladder is avoided which saves time and may  be more
omfortable [23]. Transvaginal route must be used wher-
ver  possible, particularly in obese patients [26]. The
ransvaginal approach provides a more accurate view of
he  internal structure of the ovaries, avoiding apparently
omogeneous ovaries as described with transabdomi-
al scans, particularly in obese patients. With this route,
igh-frequency probes (>7 MHz), which have a better spa-
ial  resolution can be achieved with better results. The
ecent  advent of three-dimensional (3-D) ultrasound, as
ell  as color- and pulsed-Doppler ultrasound, may  further
nhance the detection of polycystic ovaries, and may  be
ore  commonly employed in time [27]. The present study
as  hampered by the fact the study population was  virgin
nmarried female students where transvaginal ultrasound
ould not be offered.
.  Study limitations
A  referral bias could have occurred from including vol-
nteers who participated in the study. Selected cohort of
nmarried female students necessitated the application of
elvic  ultrasound which is certainly less informative than
ts  transvaginal counterpart. Another limitation is the small
ample  size, which affected the numerical strength of the
tudy  cohort.
.  Conclusion
The ultrasound diagnostic criteria of PCO have improved
he quantitative analysis of the ovarian stroma and the
bjectivity of observations. With each successive reﬁne-
ent  in the technology, the diagnostic accuracy has
volved from a mere appreciation of overall ovarian size to
he  recognition of characteristic follicular patterns of dis-
ribution  and subtle textural changes in the ovarian stroma.
he  presence of 12 or more 2–9 mm follicles appears more
ensitive than either ovarian volume or stromal brightness.
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